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ANALYSIS OF THE ASSOCIATION BETWEEN CETP Taq1B POLYMORPHISM 
(rs708272) AND CHOLESTEROL LOWERING EFFECTS AMONG STATIN USERS 
WITH HYPERLIPIDAEMIA FROM HUSM: 
A PILOT STUDY 
 
 
ABSTRACT 
 
 
Statin, a cholesterol lowering agent, is widely used for treatment of hyperlipidemia (HPL) 
nowadays. Generally, statin is effective in reducing cholesterol level. However, there is a 
marked inter-patient variation with regard to response to statin treatment possibly due to 
differences in patients’ genetic makeup, their demographic profiles, and other clinical factors. 
A single nucleotide polymorphism(SNP) in Cholesteryl Ester Transfer Protein (CETP) Taq1B 
(rs708272) gene was reported as a promising predictive genetic marker for cholesterol lowering 
effect in many populations Until now, there is no genetic association study among Malaysian 
population has been explored the influence of the particular SNP on statin’s cholesterol 
lowering effects. Hence, we aim to study the association of CETP Taq1B (rs708272) variants 
together with other clinical factors on cholesterol lowering effect of statin among HPL patients 
from Hospital Universiti Sains Malaysia (HUSM), Kelantan. This is a retrospective study 
which involves 81 HPL patients. The details regarding demographic and clinical characteristics 
of patients were obtained via interview and patient’s medical record. The genotyping of DNA 
samples of HPL patients were performed by using Polymerase Chain Reaction-Restriction 
Fragment Length Polymorphism (PCR-RFLP). The results indicate that there were no 
significant association between patients’ demographic profiles as well as clinical factors and 
their statin cholesterol lowering effects. Interestingly, variant in CETP Taq1B rs708272 has 
been associated with statin’s cholesterol lowering effects for a certain degree. In homozygous 
xiii 
 
mutant patient with B2B2 (AA) genotype has higher HDL-C level (P<0.05) than other 
genotypes (1.39±0.33 vs 1.29±0.32 and 1.26±0.29). The LDL-C and TC level were decreased 
significantly (P<0.01) in heterozygous variant patient with B1B2 (AG) genotype. While TG 
level was decreased significantly in B1 carrier. This finding warrants further multicenter 
investigation to confirm the association of the SNP with regards to the statin effectiveness on 
both LDL-C and HDL-C profile. 
xiv  
ANALISIS PERKAITAN ANTARA POLIMORFIK DALAM GEN CETP Taq1B 
(rs708272) DAN KESAN PENURUNAN KOLESTEROL DALAM KALANGAN 
PESAKIT HYPERLIPIDAEMIA YANG MENGGUNAKAN STATIN DARI HUSM: 
KAJIAN PERINTIS 
 
ABSTRAK 
 
 
Statin adalah agen penurun kolesterol yang digunakan secara meluas untuk rawatan 
hiperlipidemia (HPL) pada masa kini. Secara amnya, statin berkesan dalam mengurangkan aras 
kolesterol. Walaubagaimanapun, terdapat variasi inter-pesakit yang ketara bagi tindak balas 
terhadap rawatan dengan statin kemungkinan disebabkan oleh beberapa faktor seperti faktor 
genetik, demografi dan klinikal. Polimorfisme nukleotida tunggal (SNP) dalam gen 
“Cholesteryl Transfer Protein” (CETP) Taq1B (rs708272) dilaporkan sebagai peramal genetik 
untuk mengurangkan aras kolesterol. Sehingga kini, tiada kajian perkaitan genetik bagi SNP 
yang dikaji berkaitan dengan keberkesanan statin dalam kalangan penduduk Malaysia. Oleh 
itu, tujuan kami ialah untuk mengkaji perkaitan antara CETP Taq1B (rs708272) varian bersama 
dengan faktor klinikal yang lain terhadap kesan penurunan aras kolesterol oleh statin dalam 
kalangan pesakit HPL dari Hospital Universiti Sains Malaysia (HUSM), Kelantan. Ini adalah 
kajian retrospektif yang melibatkan 81 pesakit HPL. Butiran mengenai ciri demografi dan ciri 
klinikal pesakit telah diperolehi melalui temuduga dan rekod perubatan pesakit. Genotip 
sampel DNA pesakit HPL dilakukan dengan menggunakan teknik “Polymerase Reaction- 
Restriction Fragment Length Polymorphism” (PCR-RFLP). Keputusan menunjukkan bahawa 
tiada perkaitan yang ketara antara profil demografi pesakit dan faktor klinikal terhadapkesan 
penurunan kolesterol dalam kalangan pengguna statin. Menariknya, varian dalam CETP Taq1B 
rs708272 telah menunjukkan perkaitan dengan kesan penurunan kolesterol dalam kalangan 
pengguna statin dalam beberapa tahap tertentu. Pesakit mutan homozigot iaitu genotip B2B2 
(AA) mempunyai tahap HDL-C (P<0.05) yang lebih tinggi daripada genotip lain (1.39 ± 0.33 
xv  
vs 1.29 ± 0.32 dan 1.26 ± 0.29). Tahap LDL-C dan TC menurun dengan ketara (P<0.01) dalam 
kalangan pesakit varian heterozigot iaitu genotip B1B2 (AG). Manakala, tahap TG 
berkurangan dengan ketara dalam pembawa B1. Penemuan ini memerlukan penyelidikan yang 
lebih lanjut untuk mengesahkan perkaitan antara SNP berkenaan dengan keberkesanan statin 
berdasarkan profil LDL-C dan HDL-C. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
 
1.1 Introduction 
 
 
Hyperlipidaemia (HPL) is a high concentration of cholesterol or triglycerides in blood cause 
by several factors such as overweight, poor diet, inactive lifestyle, alcoholism, smoking, 
inherited genes and medical condition. This disease also associated with cardiovascular 
disease. In 2008, WHO revealed that the prevalence of raised cholesterol in Malaysia especially 
quite high which is 50-59.9% for both sexes. There was a study shown that by ethnic groups, 
the prevalence of HPL among Malays, Chinese, Indians and other races were 51.0%, 40.8%, 
41.6% and 34.4% respectively (Lin et al., 2018). Ministry of Health has tried their best to 
promote health awareness and produce a better treatment to ensure that the percentage of HPL 
patient reduced. As far as we concerned, the early detection of HPL and with appropriate 
intervention is crucial to a good prognosis. 
 
 
Therefore, several types of cholesterol lowering agents have been used to treat hyperlipidaemia 
patients, however statin has been the first-line treatment because of its established and 
affordability (Miziorko, 2011). Statins were structural analogues of HMG-coenzyme A 
reductase. They act by inhibiting the rate limiting enzyme (HMG-coenzyme A reductase) in 
the biosynthesis of cholesterol (mevalonate pathway) in the liver. By inhibiting this enzyme, 
statins significantly reduced plasma levels of total cholesterol (TC), LDL and ApoB. 
Meanwhile, statins also caused a modest decreased in plasma triglycerides (TG) and a small 
increased in plasma level of HDL (Eiland et al., 2010). 
2 
 
Although statin has been the first line treatment and proven efficacy in HPL patients, 
sometimes it does not apply to some patient. Interpatient variability in response to treatment 
may be associated with several factors such as age, gender, comorbidities, concomitant drug, 
supplementation and genetic variation. Several studies have demonstrated that some of this 
factor can influence cholesterol lowering effect. For example, a previous study related to 
Cholesteryl Ester Transfer Protein (CETP) Taq1B polymorphism showed that B2 allele has 
high HDL than B1B1 in atherosclerosis and protective effect such as increased HDL level was 
more significant in men than women and in non-smoker than a smoker (Rejeb et al., 2008). 
 
 
1.2 The Significant of the Study 
 
 
This study is relevant to be conducted in order to get a data regarding the prevalence and the 
factors that can affect statin effectiveness in HPL patients in our population. Until now, there 
is limited data and evidence describing this relationship in our population (Malaysian). 
 
 
Besides that, genetic variation encoded within lipid metabolism is the most prominent genetic 
factors associated with cholesterol lowering effect. However, due to discrepancy of findings 
among previous studies, no accurate genetic predictive markers for statin effectiveness have 
been identified so far. Hence the current study intended to investigate the impact of selected 
single nucleotide polymorphism (SNP) in gene encode in lipid metabolic pathway in 
cholesterol lowering effect. Genetic polymorphism in Cholesteryl Ester Transfer Protein 
(CETP) Taq1B is the potential genetic marker that associated with statin’s cholesterol lowering 
effect and of interest for this study (Li et al., 2014; Ahmed et al., 2011). 
3 
 
1.3 Objectives of the Study 
 
 
1.3.1 General Objective 
 
To analyse the association between CETP Taq1B polymorphism (rs708272) and cholesterol 
lowering effect among statin users with hyperlipidaemia from HUSM. 
 
 
1.3.2 Specific Objectives 
 
1) To perform SNP genotyping for CETP Taq1B gene (rs708272) by using Restriction 
Fragment Length Polymorphism (RFLP) method. 
 
 
2) To determine the association of CETP Taq1B polymorphism and cholesterol lowering effect 
among statin users with HPL. 
 
 
3) To determine the extent by which factors (demographic factors, clinical factors and genetic 
variant) contribute to the cholesterol lowering effect among HPL patients. 
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CHAPTER 2 
 
 
LITERATURE REVIEW 
 
 
 
2.1 Hyperlipidaemia 
 
 
2.1.1 Introduction to Hyperlipidaemia 
 
 
Hyperlipidaemia is a medical condition characterized by an elevation of any or all lipid profile 
and/or lipoproteins in the blood. It is also called hypercholesterolemia/ hyperlipoproteinemia 
(Amit et al., 2011). Although elevated low density lipoprotein cholesterol (LDL) is thought to 
be the best indicator of atherosclerosis risk, hyperlipidaemia can also be described as an 
elevated total cholesterol (TC) or triglycerides (TG), or low levels of high density lipoprotein 
cholesterol (HDL). 
 
 
Hyperlipidaemia is divided into two subtypes such as primary hyperlipidaemia and secondary 
hyperlipidaemia. Primary hyperlipidaemia usually take place as a result of genetic problems 
i.e., mutation within receptor protein, which may be due to single (monogonic) gene defect or 
multiple (polygenic) gene defect. This type may occur as a result of change in dietary and lack 
of proper physical activities. Secondary hyperlipidaemia arises as a result of other underlining 
diseases like diabetes, myxoedema, nephritic syndrome, chronic alcoholism, with use of drugs 
like corticosteroids, oral contraceptives and Beta blockers (Joseph, 2005). 
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Human body is complex machine for maintaining the homeostasis of various organ and organ 
system. Any undesirable change will disturb the balance resulting in diseased state. Lipids are 
fats in the blood stream, commonly divided into cholesterol and triglycerides. Cholesterol 
circulates in the bloodstream and is involved in the structure and function of cells. Triglycerides 
(TG) are best viewed as energy that is either used immediately or stored in fat cells. TG is 
manufactured in the liver from the foods or by being absorbed from the intestine (Ankur et al., 
2012). Arteries are normally smooth and unobstructed on the inside, but in case of increased 
lipid level, a sticky substance called plaque is formed inside the walls of arteries. This leads to 
reduced blood flow, leading to stiffening and narrowing of the arteries. It has been proved that 
elevated plasma levels of cholesterol and of LDL are responsible for atherosclerosis in man, 
and epidemiological data suggests that elevated plasma levels of HDL have a protective effect 
(Grundy and Vega, 1998). Hence, it is important to maintain lipid level to reduce the risk of 
heart disease. To maintain this lipid level, one should has LDL less than 130 mg/dL or < 70 if 
he/she has established diagnosis of diabetes, HDL greater than 40 mg/dL (men) or 50 mg/dL 
(women), Total cholesterol less than 200 mg/dL and Triglycerides less than 200 mg/dL or 150 
if he/she has established heart disease or diabetes (Barbara et al., 2005). 
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2.1.2 Epidemiology of Hyperlipidaemia 
 
 
According to WHO Global estimates, hyperlipidaemia caused one third of ischemic heart 
disease and one fifth of global cerebrovascular disease and equated to nearly 2.6 million deaths 
every year worldwide (WHO, 2014). Previous studied showed that various lipid abnormalities 
such as increased total and low- density lipoprotein cholesterol, low concentration of high- 
density lipoprotein cholesterol and high triglycerides concentrations and their combinations 
have been implicated as potential independent predictors of CVD (Supiyev et al, 2017). 
Cardiovascular disease (CVD) has been reported as a leading cause of death among adults in 
the United State and people with hyperlipidaemia was at roughly twice the risk of developing 
CVD as compared to those with normal total cholesterol level (Samantha, 2017). 
 
 
 
 
 
Figure 2.1: Hyperlipidaemia (Mayo Clinic, 2017) 
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This health problem was a common illness in Asia especially in Malaysia. This kind of disease 
caused by overweight, poor diet, inactive lifestyle, alcoholic, smoking, inherited genes and 
medical condition (Kathleen, 2017). 
 
 
The raised of total cholesterol was a major cause of disease burden in both the developed and 
developing world as a risk factor for ischemic heart disease and stroke. In 2008 the global 
prevalence of raised total cholesterol among adults (≥ 5.0 mmol/l) was 39% (37% for males 
and 40% for females). As per recorded, the mean total cholesterol changed little between 1980 
and 2008 which falling by less than 0.1 mmol/L per decade in men and women globally (WHO, 
2011). 
 
 
 
 
 
 
Figure 2.2: Prevalence of Raised Total Cholesterol worldwide (WHO, 2011) 
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In 2008, the prevalence of raised blood cholesterol among standardized 25+ aged of both sexes 
figure was produced by WHO which shown Europe (54%) as the highest, followed by the 
Americas (48%). The lowest were conquered by African Region (22.6 %) and South East Asian 
Region (29.0%) as stated in the figure 2.3. 
 
 
 
Figure 2.3: Prevalence of raised blood cholesterol with standardized age of both sexes 
(WHO, 2011) 
 
 
Based on the figure 2.3, the prevalence of raised cholesterol (%) in Malaysia was around 50- 
59.9% which was quite high and our Ministry of Health has tried their best to promote health 
awareness and produce a better treatment. Malaysia consisted of multi-ethnic nation with three 
major ethnic groups such as Malays (63.1%), Chinese (24.6%) and Indians (7.3%). There was 
a study shown that by ethnic groups, the prevalence of hypercholesterolemia among Malays, 
Chinese, Indians and other races were 51.0%, 40.8%, 41.6% and 34.4% respectively (Lin et 
al., 2018). 
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2.1.3 Pathogenesis of Hyperlipidaemia (HPL) 
 
 
Fats played a vital role in body’s metabolic process but if it was high, it increased the risk of 
coronary heart disease (CHD). There were two common types of lipid abnormalities either high 
blood cholesterol levels (hypercholesterolemia) or high blood triglycerides levels 
(hypertriglyceridemia) (Simeon, 2011). 
 
 
During lipid metabolism (Figure 2.4), lipoprotein helped cholesterol moved around in blood 
stream. Lipoprotein contained a nonpolar core in which molecules of hydrophobic lipid were 
packed to form an oil droplet. The core consists of triglycerides and cholesteryl esters in 
varying proportions. There are five major classes of lipoproteins including chylomicrons, very- 
low-density lipoprotein (VLDL), remnants, low-density lipoprotein (LDL), and high-density 
lipoprotein (HDL). A polar surface coat of phospholipid surrounded the core. The coat 
stabilized the lipoprotein particle so that it can remain as solution in plasma. Each lipoprotein 
particle contained specific proteins, apoproteins that were particularly exposed at the surface. 
The apoprotein binds to specific enzymes or transport proteins on cell membranes, thus 
directing the lipoprotein to its sites of metabolism. Almost all the dietary fats were absorbed 
from the intestinal lumen into the intestinal lymph and packed into chylomicrons (lipoprotein). 
These lipoproteins move into the blood stream where triglycerides hydrolyzed into glycerol 
and nonesterified fatty acids by endothelial lipoprotein lipase. After which the chylomicron 
remnants were absorbed in the liver and packaged with cholesterol, cholesteryl esters and 
ApoB100 to form VLDL. After released of VLDL into blood stream, it was converted into IDL 
by lipoprotein lipase and hepatic lipase, so phospholipids and apolipoproteins transferred back 
to HDL. Furthermore, after the hydrolysis by hepatic lipase, IDL was converted to LDL and 
loss more apolipoproteins (McLaren et al., 2011). 
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Peripheral cholesterol returned to the liver by reverse cholesterol transport pathway using 
HDLs which were originally synthesized by the liver and released into the blood. In the blood, 
HDL cholesterol was esterified by Lecithin cholesterol acyltransferase (LCAT) to cholesteryl 
ester and transferred to VLDL (lipoprotein) and chylomicrons (lipoprotein) returned to the liver 
via LDL receptor. Cholesteryl ester was transferred to LDL particles by CETP and then 
subjected to LDL-receptors mediated endocytosis. Finally, cholesteryl esters were hydrolyzed 
to cholesterol and extracted from the body as bile acid. In this way a cycle has been established 
in which LDLs deliver cholesterol to extrahepatic tissue and cholesterol was then returned from 
extrahepatic tissue via HDLs. Cholesterol in the blood originates partly from food and partly 
from de novo synthesis of cholesterol. Cholesterol was manufactured primarily in the liver and 
then carried in the bloodstream by low density lipoprotein (LDL). Cholesterol and other fats 
do not dissolve in water so cannot travel through the blood unaided. Therefore, lipoproteins 
were formed in the liver to transport cholesterol and other fats through the bloodstream. 
Cholesterol was returned to the liver from other body cells by high density lipoprotein (HDL). 
From there, cholesterol was secreted into the bile, either unchanged or after conversion to bile 
acids (Hegele et al., 2009). 
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Basically, cholesterol was essential for the formation of cell membranes and the manufacture 
of several hormones, but it was not required from the diet because the liver produces all the 
cholesterol the body needs. If blood cholesterol levels were elevated, large amounts of LDL 
(bad) cholesterol can deposited in the arterial walls. These represented the first stage in the 
narrowing of arteries (atherosclerosis). Generally, hypercholesterolemia causes no symptoms, 
so preventive measures and regular measurement of cholesterol level was important for people 
in high-risk categories. It was dangerous especially when HDL (good) cholesterol levels were 
low. Left untreated, hypercholesterolemia can eventually lead to a heart attack due to CHD or 
a stroke due to narrowed arteries supplying the brain (Simeon, 2011). 
 
 
 
 
Figure 2.4: Lipid metabolism (Wikipedia) 
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2.1.4 Risk Factors of Hyperlipidaemia (HPL) 
 
 
Cholesterol is a wax, fat-like substance made in liver and found in certain foods from animals 
such as dairy products, eggs, and meat. Blood cholesterol level was not only affected by food 
but also by how quickly body makes LDL (bad) cholesterol and disposed of it. Human body 
needed cholesterol to function properly but too much of cholesterol increased the risk of heart 
disease. In fact, body makes all the cholesterol it needs and it was not necessary to have any 
additional cholesterol from food. There were several factors that contributed to high cholesterol 
as below. 
 
 
Diet 
 
 
 
The Trans fats (found in some commercially baked cookies and crackers), saturated fat 
(mostly in food that came from animal), sugar, and (to a lesser extent) cholesterol which 
came only from animal products in the food can raise total and LDL cholesterol levels 
(Suzanne, 2018). Poor diet i.e. with a fat intake greater than 40 % of total calories, saturated 
fat intake greater than 10 % of total calories; and cholesterol intake greater than 300 
milligrams per day increased the risk of HPL (Durrington, 1995). Therefore, reduced the 
amount of saturated fat and cholesterol in food was a very important step in reducing blood 
cholesterol levels. 
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Weight 
 
 
 
Being overweight can make LDL cholesterol level go up and HDL level go down. By losing 
weight may  help  to  lower  it.  Weight  loss  also  helped  to  lower triglycerides and 
raised HDL ("good") cholesterol levels. Exercise helps boost body's HDL cholesterol while 
increased the size of the particles that make up LDL cholesterol, which makes it less harmful 
(Suzanne, 2018). 
 
 
Physical activity/exercise 
 
 
 
Regular physical activity helped to lower LDL cholesterol (the "bad" cholesterol) and raised 
HDL cholesterol (the "good" cholesterol) levels. It also helps to lose weight (Suzanne, 
2018). 
 
 
Age and Gender 
 
 
 
After menopause, a woman's LDL cholesterol level ("bad" cholesterol) goes up, as well as 
her risk for heart disease. The risk increased as women and men got older. Men aged ≥ 45 
years old and women aged ≥ 55 years old were at increased risk of high cholesterol and 
heart disease (Suzanne, 2018). 
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Family history and Heredity 
 
 
The risk of high cholesterol increased if a father or brother was affected by early heart disease 
(before age 55) or a mother or sister was affected by early heart disease (before age 65) 
(Suzanne, 2018). Heredity has also been a modifying factor for the progression of 
hyperlipidaemia as it has been noted that the genes partly determine the amount of cholesterol 
body makes (Durrington, 1995). 
 
 
Alcohol 
 
 
 
Alcohol intake increased HDL ("good") cholesterol but did not lower LDL ("bad") cholesterol. 
However, drinking too much alcohol can damage the liver and heart muscle, lead to high blood 
pressure, and raised triglycerides. Because of the risks, alcoholic beverages should not be used 
as a way to prevent heart disease (Durrington, 1995). 
 
 
Smoking 
 
 
 
Cigarette smoking damaged the walls of blood vessels, making them likely to accumulate fatty 
deposits. Smoking also lowered level of HDL cholesterol (Durrington, 1995). 
 
 
Other disease 
 
 
 
It has been noted that kidney disease, metabolic syndrome, nephrotic syndrome, underactive 
thyroid gland, polycystic ovarian syndrome can predispose to hyperlipidaemia (Durrington, 
1995). 
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2.2 Lipid Metabolism 
 
 
 
 
 
Figure 2.5: Schematic of the exogenous and endogenous lipid metabolism pathways 
(Catherine, 2014). 
 
 
Cholesterol plays a vital role in several diseases such as coronary heart disease, stroke, diabetes 
mellitus, hypertension, hyperlipidaemia, obesity and pancreatitis. Therefore, a look into lipid 
metabolism is important to understand how cholesterol has been process in our body. In lipid 
metabolism pathway, circulating cholesterol derived from either the endogenous or exogenous 
pathway (figure 2.5). All cholesterol will be packaged into lipoprotein particles as part of their 
metabolism pathway and covered with a specific complement of apolipoproteins (Catherine, 
2014). 
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As part of the endogenous pathway, the liver is responsible for the packaging of very low- 
density lipoprotein (VLDL) particles which are hydrolyses to intermediate density lipoprotein 
(IDL), returned to the liver so that they may be repackaged as low-density lipoprotein (LDL) 
then taken from the circulation by peripheral tissues. The exogenous pathway is necessary for 
the packaging and secretion of chylomicrons and their remnants utilizing both the small 
intestine and the liver. Hydrophobic lipids cholesterol and triglycerides (TG) are packaged into 
lipoprotein particles, which are coated with apolipoproteins that enable their solubility and 
transport within the circulation. ApoB100 is essential for packaging and secretion of VLDL 
particles from the liver. These surface proteins are also vital for lipoprotein transport in the 
circulation as the otherwise hydrophobic lipids would be insoluble in plasma. Lastly and 
importantly, apolipoproteins are used for lipoprotein particle recognition by their receptors, 
which is essential for their uptake into peripheral cells and removal from the circulation (Fauci 
et al. 2008). 
 
 
2.2.1 Low Density Lipoprotein (LDL) 
 
 
The endogenous pathway, which is responsible for the majority of cholesterol in circulation, 
requires the de novo synthesis of cholesterol by the liver, resulting in secretion of VLDL 
particles (Russell, 1992). The rate limiting enzyme involved in this process is 3-hydroxy-3- 
methyl-glutaryl-CoA (HMG Co-A) reductase, the key target of statin drugs which are used for 
cholesterol lowering. VLDL particles consisting of fatty acids, free cholesterol and TAG are 
packaged by and coated with the apolipoprotein apoB100, which is secreted from hepatocytes 
in the liver. 
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Like chylomicrons, circulating VLDL is acted upon by lipoprotein lipase resulting in VLDL 
remnants termed IDL particles. IDL then returns to the liver where it is hydrolyzed by hepatic 
lipase resulting in particles referred to as LDL. The major apoprotein of LDL remains the same: 
apoB100. The apoB-100 surface protein of LDL is recognized by tissue cells by the LDL 
receptor (LDLr), which is expressed on the surface of cells required cholesterol for membrane 
building. Excess cellular cholesterol may then also be subjected to the reverse cholesterol 
transport (RCT) pathway mediated by the ATP-binding cassette A-1 transporter (ABCA1), 
which enables the uptake of cholesterol by apo-AI, the main surface protein of HDL particles 
(Oram et al., 2001). 
 
 
2.2.2 Triglycerides (TG) 
 
 
The exogenous pathway refers to the absorption of dietary lipids by intestinal epithelial cells. 
Ingested lipids are packaged into chylomicron particles, which consist mainly of triglycerides, 
phospholipids and cholesterol, and are coated in the protein apolipoprotein B-48. The major 
role of chylomicrons is to transfer energy, in the form of fatty acids, to peripheral cells. This is 
mediated by the hydrolysis of triglycerides contained in circulating chylomicrons by 
lipoprotein lipase. The resulting chylomicron remnant particles are then reabsorbed by the liver 
and the cholesterol content is either used to generate new lipoprotein particles or excreted 
through the bile duct (Ramasamy, 2013). 
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2.2.3 High Density Lipoprotein (HDL) 
 
 
Excess cellular cholesterol may then also be subjected to the reverse cholesterol transport 
(RCT) pathway mediated by the ATP-binding cassette A-1 transporter (ABCA1), which 
enables the uptake of cholesterol by apo-AI, the main surface protein of HDL particles (Oram, 
2001). HDL recognized by HDL receptors expressed by the liver are taken up and the 
cholesterol is recycled to be reintroduced to new VLDL particles, or excreted by means of the 
bile duct (Russell, 1992). 
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2.3 Treatment for Hyperlipidaemia (HPL) 
 
 
2.3.1 Overview 
 
 
Currently, anti-hyperlipidaemia drugs contained five major classes (Figure 2.6) that include 
statins, fibric acid derivatives, bile acid binding resins, nicotinic acid derivatives and drugs that 
inhibit cholesterol absorption (Joseph, 2011). The most common drug prescribed in Malaysia 
was statin or ezetimibe and sometimes a combination of both drugs. Monotherapy has been 
shown to be effective in treating hyperlipidaemia, but combination therapy may be required for 
a comprehensive approach (MOH, 2011). 
 
 
2.3.2 3-Hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase Inhibitors 
(Statins). 
 
 
Statins are indicated for the prevention of cardiovascular disease and are among the most 
prescribed classes of medication (MOH, 2011). Their inhibition of HMGCR results in 
decreased intrahepatic cholesterol synthesis, upregulation of hepatocyte surface LDL-C 
receptors, increased LDL-C uptake by hepatocytes, and ultimately decreased systemic 
concentration of LDL-C (Kitzmiller et. al, 2016). There are several class of statin such as 
Lovastatin, Simvastatin, Pravastatin, Fluvastatin, Atorvastatin and Rosuvastatin. Statins 
were broadly prescribed in the treatment of hypercholesterolemia and have been linked to 
the reduced incidence of coronary morbidity and mortality in high-risk adults (Belay et al., 
2006). 
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2.3.3 Selective cholesterol absorption inhibitor (Ezetimibe) 
 
 
Ezetimibe was another LDL-lowering drug that blocked the absorption of cholesterol by the 
small intestine. Ezetimibe appeared to be safe and mostly used in patients with statin 
intolerance. Besides that, a combination with statin reduced cardiovascular events in 
patients with chronic kidney disease (Baigent et al. 2011). 
 
 
2.3.4 Fibric acid derivatives (Fibrates) 
 
 
Fibrates were primarily triglyceride-lowering agents that also lower VLDL-C. It was used 
for treatment of severe hypertriglyceridemia to prevent development of acute pancreatitis. 
Like ezetimibe, it also an alternative in people who cannot tolerate statins. The combination 
of a statin and a fibrate was attractive for mixed hyperlipidaemia (Shattat, 2014). 
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2.3.5 Nicotinic acid derivatives (Niacin) 
 
 
Niacin effectively lowered triglycerides, moderately raised HDL-C and moderately reduced 
LDL-C. It was a water-soluble vitamin of type B and the oldest lipid lowering agent used 
to treat hyperlipidaemia and proved to decrease cardiovascular morbidity and total 
mortality. In the previous study shown that niacin combined with a statin reduced 
subclinical atherosclerosis. On the other hand, for patients with statin intolerance, the 
combination of niacin and ezetimibe can effectively lower LDL-C levels (Jelesoff et al., 
2006). 
 
 
 
 
Figure 2.6: Lipid lowering agents (Isam, 2016) 
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2.4 Statin as First Therapy for Hyperlipidaemia 
 
 
Statins are powerful LDL lowering drugs. They blocked cholesterol synthesis in the liver and 
raised LDL receptors, which removed LDL from the blood stream (Figure 2.7). Statins also 
lowered VLDL, the other atherogenic lipoprotein. These agents reduce LDL-C by 25-55%. 
Statins have proven to be safe for most patients (Pasternak et al., 2002). They did not cause 
liver disease, cataracts, or hemorrhagic stroke. Rare patients experienced muscle damage 
characterized by marked elevations of creatine kinase, rhabdomyolysis, hemoglobinuria and 
acute renal failure. This was most likely to occur in who have complex medical problems 
(concurrent disease) and/or who were taking multiple medications (concomitant drugs). 
Recently statins have been linked to new onset diabetes (Preiss et al., 2011). Most cases of 
diabetes occur in patients who already have borderline diabetes. Occasional patients complain 
of cognitive dysfunction while taking statins. The possibility of these side effects indicated that 
statin therapy must balance benefit versus risk. Fortunately, the risk for serious side effects was 
low. 
 
 
2.4.1 Mechanism of Action of Statin 
 
 
Most of the cholesterol that courses through the circulation does not enter the system directly 
from dietary sources. Rather, it is synthesized in the smooth endoplasmic reticulum by means 
of a series of chemical reactions that at one point are catalyzed by HMG CoA reductase. The 
first way to block cholesterol synthesis is by interrupting the conversion of HMG CoA to 
mevalonate (so that mevalonate cannot generate cholesterol). In order for HMG CoA to 
become mevalonate, the reaction must be catalyzed by the enzyme HMG CoA reductase. If 
this enzyme is blocked, mevalonate cannot be generated and cholesterol cannot be synthesized. 
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This is the principal mechanism of action of the most popular and most effective of the 
"cholesterol-blocking" medicines, the HMG CoA reductase inhibitors, which are collectively 
known as "statins". By inhibiting this enzyme (HMG CoA reductase), statins significantly 
reduced plasma levels of total cholesterol (TC), LDL and ApoB. Meanwhile, statins also 
caused a modest decreased in plasma triglycerides and a small increased in plasma level of 
HDL (Eiland et al., 2010). 
 
 
Since statin increase HDL level and decrease triglycerides level, Cholesteryl Ester Transfer 
Protein (CETP) also contribute to both of this cholesterol. CETP is involved in reverse 
cholesterol transport from peripheral tissues. This reverse transport pathway is responsible for 
HDL level. CETP TaqIB genotype seems to be associated with modified HDL response; 
individuals with the B1B1 genotype have been reported to display the greatest HDL increases 
in response to statins (Zineh, 2007). 
 
 
Figure 2.7: Statin-Mechanism of Action (Medscape) 
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2.5 Cholesteryl Ester Transfer Protein (CETP) 
 
 
2.5.1 Overview of CETP 
 
 
Cholesteryl ester transfer protein (CETP) gene is also called as a plasma lipid transfer 
protein, was located on the 16th chromosome. Based on figure 2.8, CETP is a hydrophobic 
plasma glycoprotein that secreted mainly from the liver and circulates in plasma, bound 
mainly to HDL. It facilitates the transport of cholesteryl esters and triglycerides between 
the lipoproteins by collected triglycerides from a very low density (VLDL) or low density 
lipoprotein (LDL) and exchanged them for cholesteryl esters from high density lipoprotein 
(HDL) and vice versa. A CETP deficiency is linked to increased HDL levels and decreased 
LDL levels (Durrington, 2012). 
 
 
 
 
 
 
 
Figure 2.8: CETP Pathway (Shah, 2007) 
